Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SGMS2 | Q8NHU3 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046789 | 1.00 | SGMS2 (0.52) | SGMS2NPC1HTTGAALIPE | |
| SCHEMBL10442994 | 1.00 | SGMS2 (0.52) | SGMS2NPC1HTTGAALIPE | |
| SCHEMBL1097807 | 0.89 | SGMS2 (0.57) | SGMS2NPC1HTTGAAMEN1 | |
| SCHEMBL7164705 | 0.89 | SGMS2 (0.57) | SGMS2NPC1HTTGAAMEN1 | |
| SCHEMBL712291 | 0.89 | SGMS2 (0.57) | SGMS2NPC1HTTGAAMEN1 | |
| SCHEMBL8827709 | 0.87 | SGMS2 (0.56) | SGMS2NPC1HTTGAALIPE | |
| SCHEMBL9730334 | 0.85 | SGMS2 (0.47) | SGMS2NPC1HTTGAALIPE | |
| SCHEMBL9647587 | 0.85 | SGMS2 (0.47) | SGMS2NPC1HTTGAALIPE | |
| SCHEMBL10864744 | 0.84 | SGMS2 (0.56) | SGMS2NPC1HTTGAALIPE | |
| SCHEMBL7768796 | 0.83 | PDE4A (0.47) | MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308825-B1 | Process for the preparation of an intermediate for azoxystrobin | SYNGENTA LTD (GB) | 2014-05-21 | — | — | EP | disclosed |
| EP-1891020-B1 | PROCESSES FOR THE PREPARATION OF AZOXYSTROBIN USING DABCO AS A CATALYST AND NOVEL INTERMEDIATES USED IN THE PROCESSES | SYNGENTA LTD (GB) | 2013-06-05 | — | — | EP | disclosed |
| US-20080214587-A1 | Processes For the Preparation of Azoxystrobin Using Dabco as a Catalyst and Novel Intermediates Used in the Processes | SYNGENTA CROP PROTECTION, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1891020-A2 | PROCESSES FOR THE PREPARATION OF AZOXYSTROBIN USING DABCO AS A CATALYST AND NOVEL INTERMEDIATES USED IN THE PROCESSES | Syngenta Limited (GB) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006114572-A2 | PROCESSES FOR THE PREPARATION OF AZOXYSTROBIN USING DABCO AS A CATALYST AND NOVEL INTERMEDIATES USED IN THE PROCESSES | SYNGENTA LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214587-A1 | Processes For the Preparation of Azoxystrobin Using Dabco as a Catalyst and Novel Intermediates Used in the Processes | DDT, AOC3, DAO | SGMS2 4000/4885NPC1 4635/4885HTT 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.